001     1055046
005     20260225202306.0
024 7 _ |a 10.3390/analytica7010015
|2 doi
024 7 _ |a 10.34734/FZJ-2026-01838
|2 datacite_doi
037 _ _ |a FZJ-2026-01838
082 _ _ |a 540
100 1 _ |a Jonas, Alissa
|0 P:(DE-Juel1)196963
|b 0
|u fzj
245 _ _ |a Development and Validation of an UHPLC-ESI-QTOF-MS Method According to the ICH M10 Guideline for Quantification of the Clinical Drug Candidate RD2 in the Mouse Brain
260 _ _ |a Basel
|c 2026
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1771997333_12427
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The all-D-enantiomeric-peptide RD2 was developed for the treatment of Alzheimer’s disease. This study aimed to develop a specific and highly sensitive liquid chromatographymass-spectrometric (UHPLC-ESI-QTOF) method for quantifying RD2 in the mouse brainand to validate it according to the ICH M10 guideline to investigate the pharmacokinetic profile of RD2 in its target organ. Sample preparation, chromatographic separation and quantification were very challenging due to RD2’s highly hydrophilic properties, the complex matrix and the required lower limit of quantification (LLOQ). Chromatographic separation was performed on an Acquity UPLC BEH C18 column (2.1 × 100 mm, 1.7 μm particle size) within 5 min at 50 ◦C with a flow rate of 0.5 mL·min−1. Mobile phasesconsisted of water and acetonitrile with 0.2% formic acid and 0.015% heptafluorobutyric acid. Ions were generated by electrospray ionization in the positive mode, and RD2 was quantified by QTOF-MS. The developed extraction method revealed complete recovery.The linearity of the calibration curve was in the range of 2 ng·mL−1 to 500 ng·mL−1 (R2 > 0.99) with a LLOQ of 5 ng·mL−1. The intraday and interday accuracy and precision ranged from 0.4% to 12.2% and from 1.0% to 12.0%. RD2 remained stable in thefreshly homogenized brain even after several freeze–thaw cycles, but stability decreased over time during long-term storage at −80 ◦C. Using this validated method, RD2-spiked brain homogenate samples and samples of a pharmacokinetic study with RD2 in micewere analyzed.
536 _ _ |a 5244 - Information Processing in Neuronal Networks (POF4-524)
|0 G:(DE-HGF)POF4-5244
|c POF4-524
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Gering, Ian
|0 P:(DE-Juel1)171922
|b 1
700 1 _ |a Schartmann, Elena
|0 P:(DE-Juel1)166069
|b 2
700 1 _ |a Schemmert, Sarah
|0 P:(DE-Juel1)165908
|b 3
700 1 _ |a Willbold, Dieter
|0 P:(DE-Juel1)132029
|b 4
700 1 _ |a Santiago-Schübel, Beatrix
|0 P:(DE-Juel1)133853
|b 5
700 1 _ |a Kutzsche, Janine
|0 P:(DE-Juel1)159137
|b 6
|e Corresponding author
773 _ _ |a 10.3390/analytica7010015
|g Vol. 7, no. 1, p. 15 -
|0 PERI:(DE-600)3035770-6
|n 1
|p 15 -
|t Analytica
|v 7
|y 2026
|x 2673-4532
856 4 _ |u https://juser.fz-juelich.de/record/1055046/files/analytica-07-00015-v2.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:1055046
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)196963
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)171922
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)132029
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 5
|6 P:(DE-Juel1)133853
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 6
|6 P:(DE-Juel1)159137
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-524
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Molecular and Cellular Information Processing
|9 G:(DE-HGF)POF4-5244
|x 0
914 1 _ |y 2026
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0112
|2 StatID
|b Emerging Sources Citation Index
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-04-12T14:55:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-04-12T14:55:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-11-11
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-11-11
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)IBI-7-20200312
|k IBI-7
|l Strukturbiochemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)IBI-7-20200312
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21